Analysts Set Retrophin Inc. (RTRX) Price Target at $31.67
Shares of Retrophin Inc. (NASDAQ:RTRX) have earned a consensus rating of “Buy” from the six ratings firms that are currently covering the firm. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $31.67.
A number of analysts recently commented on RTRX shares. JMP Securities reiterated a “buy” rating on shares of Retrophin in a research report on Friday, November 4th. Zacks Investment Research upgraded Retrophin from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Wednesday, October 12th. BMO Capital Markets lifted their price objective on Retrophin from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, November 21st. Leerink Swann lifted their price objective on Retrophin from $27.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 7th. Finally, TheStreet cut Retrophin from a “hold” rating to a “sell” rating in a research report on Friday, November 4th.
In other Retrophin news, CEO Steve Aselage sold 8,200 shares of Retrophin stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $21.12, for a total value of $173,184.00. Following the completion of the sale, the chief executive officer now owns 248,756 shares in the company, valued at approximately $5,253,726.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Alvin Shih sold 8,750 shares of Retrophin stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $16.24, for a total value of $142,100.00. Following the completion of the sale, the executive vice president now owns 158,334 shares of the company’s stock, valued at approximately $2,571,344.16. The disclosure for this sale can be found here. 2.41% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of the stock. BlackRock Fund Advisors boosted its stake in Retrophin by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,302,989 shares of the biopharmaceutical company’s stock valued at $17,799,000 after buying an additional 22,903 shares during the period. GSA Capital Partners LLP boosted its stake in Retrophin by 68.6% in the second quarter. GSA Capital Partners LLP now owns 46,509 shares of the biopharmaceutical company’s stock valued at $828,000 after buying an additional 18,920 shares during the period. Boston Advisors LLC boosted its stake in Retrophin by 23.8% in the second quarter. Boston Advisors LLC now owns 26,945 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 5,185 shares during the period. First Mercantile Trust Co. boosted its stake in Retrophin by 35.4% in the second quarter. First Mercantile Trust Co. now owns 5,930 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 1,550 shares during the period. Finally, Bank of Montreal Can acquired a new stake in Retrophin during the second quarter valued at approximately $368,000.
Shares of Retrophin (NASDAQ:RTRX) opened at 21.64 on Wednesday. The firm’s market cap is $816.52 million. Retrophin has a 12 month low of $11.60 and a 12 month high of $24.57. The stock’s 50 day moving average is $20.48 and its 200 day moving average is $19.02.
Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by $0.47. The firm had revenue of $33.95 million for the quarter, compared to analyst estimates of $34.84 million. Retrophin had a negative return on equity of 1.33% and a negative net margin of 32.96%. The company’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.05) EPS. On average, analysts anticipate that Retrophin will post ($1.32) earnings per share for the current fiscal year.
Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.